A possible link between Trousseau's syndrome and tissue factor producing plasma cells

American Journal of Hematology

Volumn 84, Issue 6, 2009, Pages 382-385

  Shimizu, Kazuyuki ^a   Itoh, Junji ^a  

^a Nagoya City Midori General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; VINCRISTINE; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; HYPERCOAGULABILITY; LEG PHLEBOGRAPHY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; THROMBOPHLEBITIS; TROUSSEAU SYNDROME;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SYNDROME; THROMBOPHLEBITIS; THROMBOPLASTIN;

EID: 66849131716     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21419     Document Type: Article

References (15)

1. Varki A. Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood 2007;110:1723-1729. (Pubitemid 47443881)
2. Callander N, Rapaport SI. Trousseau's syndrome. West J Med 1993;158:364-371. (Pubitemid 23111598)
3. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249-266.
4. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007;7:307-315. (Pubitemid 46488336)
5. Negaard HFS, Iversen PO, Østenstrad B, et al. Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. Thromb Haemost 2008;99:1040-1048.
6. Di Nisio M, Otten MO, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 2005;3:2391-2396. (Pubitemid 41727152)
7. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757. (Pubitemid 36718191)
8. Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997;55:169-174. (Pubitemid 27360051)
9. Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004;101:558-566. (Pubitemid 38970607)
10. Matsuzaki H, Hata H, Sonoki T, et al. Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 1995;61:131-137.
11. Ayliffe MJ, Davies FE, de Castro D, Morgan GJ. Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica 2007;92:1135-1138. (Pubitemid 350144224)
12. Shimizu K, Murate T, Kunii A. Circulating immunoglobulin-secreting cells in patients with plasma cell dyscrasia. Blood 1980;55:590-594. (Pubitemid 10138840)
13. Shimizu K, Ohnishi K, Kunii A. Differentiation of benign monoclonal gammopathy and smouldering multiple myeloma from frank myeloma. Clin Exp Immunol 1982;50:596-600. (Pubitemid 13249345)
14. Vallet S, Palumbo A, Raje N, et al. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 2008;49:1238-1245.
15. Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thrmoboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143:222-229.